NASDAQ:BPMC - Blueprint Medicines Stock Price, Forecast & News

Blueprint Medicines trades on the NASDAQ under the ticker symbol "BPMC."

Blueprint Medicines Corp (NASDAQ:BPMC) announced its quarterly earnings data on Thursday, February, 13th. The biotechnology company reported ($1.35) earnings per share for the quarter, beating analysts' consensus estimates of ($1.71) by $0.36. The biotechnology company earned $51.53 million during the quarter, compared to the consensus estimate of $26 million. Blueprint Medicines had a negative net margin of 522.75% and a negative return on equity of 72.52%. The company's revenue for the quarter was up 4888.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.83) EPS. View Blueprint Medicines' Earnings History.

Blueprint Medicines is scheduled to release their next quarterly earnings announcement on Thursday, May 14th 2020. View Earnings Estimates for Blueprint Medicines.

12 brokerages have issued 1-year price objectives for Blueprint Medicines' stock. Their forecasts range from $70.00 to $125.00. On average, they anticipate Blueprint Medicines' stock price to reach $104.08 in the next twelve months. This suggests a possible upside of 67.9% from the stock's current price. View Analyst Price Targets for Blueprint Medicines.

12 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Blueprint Medicines in the last year. There are currently 3 hold ratings, 8 buy ratings and 1 strong buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Blueprint Medicines.

News headlines about BPMC stock have trended extremely negative on Monday, according to InfoTrie Sentiment. The research group ranks the sentiment of press coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Blueprint Medicines earned a news sentiment score of -5.0 on InfoTrie's scale. They also assigned press coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the next several days. View News Stories for Blueprint Medicines.

Some companies that are related to Blueprint Medicines include Teva Pharmaceutical Industries (TEVA), Elanco Animal Health (ELAN), Mylan (MYL), Beigene (BGNE), Ono Pharmaceutical (OPHLF), Sarepta Therapeutics (SRPT), Bausch Health Companies (BHC), Catalent (CTLT), Ionis Pharmaceuticals (IONS), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Dr.Reddy's Laboratories (RDY), ACADIA Pharmaceuticals (ACAD), Ascendis Pharma A/S (ASND) and The Medicines (MDCO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Blueprint Medicines investors own include Advanced Micro Devices (AMD), Micron Technology (MU), Canopy Growth (CGC), Nektar Therapeutics (NKTR), AbbVie (ABBV), Ionis Pharmaceuticals (IONS), Stratasys (SSYS), STMicroelectronics (STM), Global Blood Therapeutics (GBT) and Intercept Pharmaceuticals (ICPT).

(BPMC) raised $115 million in an initial public offering (IPO) on Thursday, April 30th 2015. The company issued 7,200,000 shares at a price of $15.00-$17.00 per share. Goldman Sachs and Cowen and Company served as the underwriters for the IPO and JMP Securities and Wedbush PacGrow were co-managers.

Blueprint Medicines' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Cadian Capital Management LP (4.00%), State Street Corp (3.81%), Alliancebernstein L.P. (2.08%), Westfield Capital Management Co. LP (1.57%) and Eagle Asset Management Inc. (1.55%). Company insiders that own Blueprint Medicines stock include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Institutional Ownership Trends for Blueprint Medicines.

BPMC stock was sold by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Pictet Asset Management Ltd., Perceptive Advisors LLC, BVF Inc. IL, Victory Capital Management Inc., Westfield Capital Management Co. LP, Victory Capital Management Inc. and Spark Investment Management LLC. Company insiders that have sold Blueprint Medicines company stock in the last year include Alexis Borisy, Anthony L Boral, Ariel Hurley, Charles A Rowland Jr, George Demetri, Jeffrey W Albers, Kate Haviland, Lonnel Coats, Marion Dorsch and Nicholas Lydon. View Insider Buying and Selling for Blueprint Medicines.

BPMC stock was purchased by a variety of institutional investors in the last quarter, including Cadian Capital Management LP, Point72 Asset Management L.P., Candriam Luxembourg S.C.A., Credit Suisse AG, Barclays PLC, Alliancebernstein L.P., Jane Street Group LLC and Sectoral Asset Management Inc. View Insider Buying and Selling for Blueprint Medicines.

Shares of BPMC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BPMC stock can currently be purchased for approximately $62.00.

Blueprint Medicines has a market capitalization of $3.35 billion and generates $66.51 million in revenue each year. The biotechnology company earns $-347,690,000.00 in net income (profit) each year or ($7.27) on an earnings per share basis. Blueprint Medicines employs 217 workers across the globe.View Additional Information About Blueprint Medicines.

The official website for Blueprint Medicines is http://www.blueprintmedicines.com/.

Blueprint Medicines' mailing address is 45 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 617-374-7580 or via email at [email protected]